News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides current stock information for ProQR Therapeutics NV (PRQR), including its recent trading performance, market capitalization, and links to financial data and analyst ratings. It notes that more news is expected soon for the company. The stock closed at $1.875, down 1.32%.
This article provides an earnings forecast for ProQR Therapeutics NV (PRQR), indicating a current earnings forecast score of 8.67 and a ranking of 74 out of 387 in its industry. Analysts have set an average price target of $9.50 with a "Buy" rating. The …
This article provides financial information for ProQR Therapeutics N.V. (MUN:0PQ) focusing on its enterprise value to EBIT forward. It indicates that the market for this stock was closed with no trades. The content primarily lists various financial data points and market analysis tools available …
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy. The average 12-month price target is $7.33, significantly higher than the recent share price of $1.71. Despite missing revenue estimates, the company …
An insider at ProQR Therapeutics N.V. (NASDAQ: PRQR) recently purchased shares valued at $353,960. This transaction was disclosed in a recent SEC filing. ProQR Therapeutics is a biotechnology company focused on developing RNA-based therapeutics for severe genetic disorders.
ProQR Therapeutics N.V. CEO Daniel Anton de Boer recently purchased 200,000 Ordinary Shares at $1.7698 per share, increasing his direct holdings to 500,000 shares. This transaction, categorized as an open market or private purchase, was disclosed in a Form 4 filing and indicates a …
ProQR Therapeutics N.V. (NASDAQ: PRQR) generated $19.14 million in revenue last year, with its RNA Based Therapeutics segment being the top performer, contributing $17.95 million. The United States was the primary geographic contributor, also accounting for $17.95 million. This represents a slight decrease from …
This amended Schedule 13D/A filing details that the Van Herk reporting persons, holding 10.9% of ProQR Therapeutics N.V., have initiated a petition for a governance investigation and the appointment of an independent non-executive director. The petition was filed on July 27, 2026, with the …
Short interest in ProQR Therapeutics (NASDAQ:PRQR) surged by 92.5% in July, reaching 2.31 million shares, representing 2.4% of outstanding shares and 1.8 days to cover. Despite a mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.33, the …
ProQR Therapeutics (NASDAQ:PRQR) is set to announce its Q2 2026 earnings before market open on Thursday, August 6th, with an earnings call scheduled for August 11th. Analysts project a loss of $0.14 per share on revenue of $4.56 million, following a previous quarter where …
Aberdeen Group plc and its affiliate abrdn Inc. have disclosed a beneficial ownership of 8,932,507 Ordinary Shares in ProQR Therapeutics N.V., representing 6.33% of the class. Both entities report shared voting and dispositive power over these shares, which abrdn Inc. holds on behalf of …
This article provides a comprehensive stock analysis of ProQR Therapeutics NV (PRQR), highlighting its healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from analysts with a target price …
ProQR Therapeutics Director Bart Filius increased his stake in the company by purchasing 150,000 shares for $258,000, doubling his total ownership to 300,000 shares. This follows a similar purchase in June. Shares of ProQR (NASDAQ:PRQR) traded down slightly and the company, valued at $181.75 …
Eli Lilly and Company has reported a beneficial ownership of 21,995,880 ordinary shares in ProQR Therapeutics N.V., representing a 15.6% stake. This information was disclosed in an amended Schedule 13G/A filing, indicating that Eli Lilly holds sole voting and dispositive power over all these …
The article reports on the institutional confidence score for ProQR Therapeutics NV (PRQR), which currently stands at 3.00, ranking 192nd in the Biotechnology & Medical Research industry. Institutional shareholding has decreased by 4.80% quarter-over-quarter to 36.39%. Steven Cohen is noted as the largest institutional …
This article from TradingKey attempts to provide a revenue breakdown for ProQR Therapeutics NV (PRQR) but states that relevant data have not been disclosed by the company. It mentions the company's current stock price, market capitalization, and provides a framework for how revenue data …
Bart Filius, a Director at ProQR Therapeutics NV (PRQR), recently purchased 150,000 shares, increasing his total holdings to 300,000 shares. This transaction reflects a positive insider sentiment, with four insider buys and no sells over the past year. ProQR Therapeutics NV's stock, trading at …
An insider at Proqr Therapeutics N.v. recently purchased shares valued at $257,925. This transaction was disclosed in a recent SEC filing, indicating a significant investment by an insider in the company.
Bart Filius, a director at ProQR Therapeutics N.V. (PRQR), purchased 150,000 Ordinary Shares of the company on July 17, 2026, at a price of $1.7195 per share. Following this transaction, Filius directly holds 300,000 Ordinary Shares. This open market purchase was not made under …
ProQR Therapeutics N.V. (PRQR) has filed an EFFECT form with the SEC, indicating the effectiveness of its F-3 shelf registration statement as of July 15, 2026, at 4:00 P.M. The filing was accepted by SEC EDGAR on July 16, 2026, at 12:15 AM EDT. …
ProQR Therapeutics N.V. is registering for resale up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company states it will not receive any proceeds from this offering. ProQR is a clinical-stage biotechnology company …
Aescap group and Patrick Krol have filed a Schedule 13G/A, disclosing their shareholdings in ProQR Therapeutics N.V. The filing indicates that Aescap Life Sciences, Aescap Genetics, Inspirational Visions, and Patrick Krol himself hold varying percentages of ProQR's ordinary shares, with Patrick Krol beneficially owning …
Search by ticker symbol or company name and select a result to open its chart.